# ROMULUS (NCT01691898)

> A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01691898
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Genentech, Inc.
- Conditions: Follicular Lymphoma; Diffuse Large B-Cell Lymphoma
- Interventions: Obinutuzumab; Pinatuzumab Vedotin; Polatuzumab Vedotin; Rituximab
- Enrollment: 231
- Primary outcome: Percentage of Participants With a Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)
- Primary outcome: Duration of Objective Response (DOR) as Determined by Modified Response and Progression Criteria for NHL: Rituximab Containing Regimens (Arms A and B, Cohort C)
- Primary outcome: Percentage of Participants With CR at End of Treatment (EOT) Based on Positron Emission Tomographic/Computed Tomography (PET/CT) Assessment Determined by Independent Review Committee (IRC) Per Lugano 2014 Response Criteria: Cohorts E, G, and H

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 5
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=romulus-nct01691898